Type I interferons (IFNs) have strong antitumour activity yet their clinical use is limited by their off-target toxicity and by their effect on immune evasion. Here the authors design a biomimetic nanoparticle loaded with an IFN inducer, which can at the same time replenish intratumoural IFNs and reduce their immunosuppressive activity, showing therapeutic efficacy in several animal tumour models.
- Yihui Zhai
- Jinming Wang
- Yaping Li
